Avenue Therapeutics (NASDAQ:ATXI) Shares Climb 6.7% – What’s Next?

Avenue Therapeutics, Inc. (NASDAQ:ATXI) rose 6.7% during mid-day trading on Thursday. The stock traded as high as $0.4289 and last traded at $0.4289. Approximately 117 shares changed hands during mid-day trading, a decline of 98% from the average session volume of 6,508 shares. The stock had previously closed at $0.4019.

Avenue Therapeutics Price Performance

The company’s fifty day moving average price is $0.47 and its 200 day moving average price is $0.36. The company has a market cap of $1.41 million, a PE ratio of 0.02 and a beta of -0.32.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc is a clinical-stage specialty pharmaceutical company focused on developing and commercializing therapies for acute pain. The company has concentrated primarily on hospital-based treatments, with the goal of addressing pain management needs while offering alternatives to conventional opioid therapies.

Avenue’s lead product candidate is intravenous (IV) tramadol, an investigational formulation of tramadol hydrochloride intended for the management of acute postoperative pain in adults who require an intravenous analgesic.